1. GPCR/G Protein
  2. Adenosine Receptor

Adenosine Receptor

Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which mediate the physiological actions of adenosine. To date, four AR subtypes have been cloned and identified in different tissues. These receptors have distinct localization, signal transduction pathways and different means of regulation upon exposure to agonists. A key property of some of Adenosine receptors is their ability to serve as sensors of cellular oxidative stress, which is transmitted by transcription factors, such as NF-κB, to regulate the expression of ARs. The importance of Adenosine receptors in the regulation of normal and pathological processes such as sleep, the development of cancers and in protection against hearing loss will be examined.

Adenosine Receptor Related Products (51):

Cat. No. Product Name Effect Purity
  • HY-13201A
    CGS 21680 Hydrochloride Agonist 99.70%
    CGS 21680 Hydrochloride is a selective adenosine A2A receptor agonist with a Ki of 27 nM.
  • HY-10889
    Preladenant Antagonist 99.08%
    Preladenant is a potent and competitive antagonist of the human adenosine A2A receptor with a Ki of 1.1 nM and has over 1000-fold selectivity over other adenosine receptors.
  • HY-19532
    ZM241385 Antagonist 98.55%
    ZM 241385 is a selective and high affinity A2A adenosine receptor antagonist.
  • HY-B0809
    Theophylline Inhibitor 99.94%
    Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.
  • HY-19533
    SCH 58261 Antagonist 99.38%
    SCH 58261 is the adenosine A2A receptor competitive antagonist. Displays 323-, 53- and 100-fold selectivity over A1, A2B and A3 receptors, respectively.
  • HY-103186
    MRS-1706 Antagonist
    MRS-1706 is a potent and selective A(2B) adenosine receptor antagonist with a Ki value of 1.39 nM.
  • HY-112840
    ST3932 Antagonist
    ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A2A receptor, with Kis of 8 nM and 33 nM for A2A and A1 receptors, respectively.
  • HY-120090
    MRS1177 Antagonist
    MRS1177 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 0.3 nM.
  • HY-101978
    CPI-444 Inhibitor 99.94%
    CPI-444 is a potent and selective inhibitor of A2A receptor (A2AR) induces antitumor responses.
  • HY-10857
    Vipadenant Antagonist 98.28%
    Vipadenant (BIIB-014; CEB-4520) is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively.
  • HY-10888
    Istradefylline Antagonist 99.42%
    Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
  • HY-101980
    AZD4635 Inhibitor 99.79%
    AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.
  • HY-10995
    Tozadenant Antagonist 98.06%
    Tozadenant is an adenosine A2A receptor antagonist, with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A.
  • HY-100747
    PSB-12379 Inhibitor 99.99%
    PSB-12379 is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
  • HY-14917
    Capadenoson Agonist 98.43%
    Capadenoson is a selective agonist of adenosine-A1 receptor.
  • HY-12365
    Namodenoson Agonist 99.51%
    Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.
  • HY-103173
    5'-N-Ethylcarboxamidoadenosine Agonist 99.86%
    5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.
  • HY-18939
    N6-Cyclohexyladenosine Agonist 99.98%
    N6-Cyclohexyladenosine is a selective A1 receptor agonist (EC50 = 8.2 nM).
  • HY-B0153A
    Ticlopidine hydrochloride Inhibitor 99.99%
    Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.
  • HY-103695
    CD73-IN-1 Inhibitor 98.78%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.